Precigen Gives Business Updates, Significant Progress Made In The Development Of The PRGN-2012 Adenoverse Immunotherapy For The Treatment Of RRP; Plans To Submit A BLA Under An Accelerated Approval Pathway In 2H Of 2024
Precigen Gives Business Updates, Significant Progress Made In The Development Of The PRGN-2012 Adenoverse Immunotherapy For The Treatment Of RRP; Plans To Submit A BLA Under An Accelerated Approval Pathway In 2H Of 2024
– Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the second half of 2024; ramping up commercial readiness activities for a potential launch in 2025 –
— 用於治療RRP的 PRGN-2012 AdenOverse免疫療法的開發取得了重大進展;Precigen計劃在2024年下半年根據加速批准途徑提交BLA;加大可能在2025年推出的商業準備活動—
– Precigen's PRGN-2012 received the first Breakthrough Therapy Designation and accelerated approval pathway from the FDA for the treatment of RRP –
— Precigen 的 PRGN-2012 獲得了 FDA 的首個突破性療法稱號和加速批准途徑,用於治療 RRP —
– Precigen received IND clearance for a randomized Phase 2 study of PRGN-2009 AdenoVerse immunotherapy in combination with pembrolizumab in HPV-associated recurrent/metastatic cervical cancer; study now active and recruiting patients –
— Precigen 獲得 PRGN-2009 AdenoVerse 免疫療法與 pembrolizumab 聯合治療人乳頭瘤病毒相關復發/轉移性宮頸癌的隨機 2 期研究的臨床許可;該研究目前正在進行並正在招募患者 —
– Interim data from the ongoing Phase 1b study of PRGN-3006 UltraCAR-T in relapsed/refractory AML anticipated in the second half of 2024 –
— 正在進行的針對復發/難治性急性髓細胞白血病的 PRGN-3006 Ultracar-T 1b 期研究的中期數據預計將於 2024 年下半年發佈 —
– Preliminary data from the Phase 1 study of PRGN-3007 next generation UltraCAR-T in ROR1+ advanced cancers anticipated in the second half of 2024 –
— 針對 ROR1+ 晚期癌症的 PRGN-3007 下一代 Ultracar-T 的 1 期研究的初步數據預計將於 2024 年下半年發佈 —
– Cash, cash equivalents, short-term and long-term investments totaled $62.9 million as of December 31, 2023 –
— 截至2023年12月31日,現金、現金等價物、短期和長期投資總額爲6,290萬美元—
– Continued focus on cost containment resulted in a reduction in SG&A costs of 16% for the twelve months ended December 31, 2023, compared to the prior year period –
— 在截至2023年12月31日的十二個月中,持續關注成本控制使銷售和收購成本與去年同期相比降低了16%——